Key Highlights
- $8.5 million investment in SpliSense by the Cystic Fibrosis Foundation to advance Phase 2 clinical trials.
- The trial focuses on an inhaled ASO drug for CF patients with splicing mutations, potentially offering new treatment avenues.
- Previous funding includes $8.4 million in 2021 and $400,000 in 2017, part of the Foundation’s $500 million Path to a Cure initiative.
Source: Business Wire
Notable Quote
- “We continue to pursue diverse strategies to develop potential treatments for people with CF who can’t benefit from existing modulator therapies,” – Steven M. Rowe, MD, Executive Vice President and Chief Scientific Officer at Cystic Fibrosis Foundation
SoHC's Take
The Cystic Fibrosis Foundation’s recent funding decision marks a significant step forward in the fight against cystic fibrosis, particularly for individuals with specific splicing mutations and other rare mutations. By investing up to $8.5 million in additional funds in SpliSense, the Foundation is not only supporting the advancement of a potentially groundbreaking inhaled antisense oligonucleotide (ASO) drug but also underscoring its commitment to diversifying treatment strategies beyond current modulator therapies. This move could pave the way for new therapeutic approaches, offering hope to those with cystic fibrosis who have limited treatment options. The dedication of resources to such innovative research demonstrates a robust commitment to accelerating the path to a cure for all affected by this challenging condition.
